N-Hydroxy-N′-aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3324-3328

  Basu, Arijit ^a   Sinha, Barij N ^a   Saiko, Philipp ^b   Graser, Geraldine ^b   Szekeres, Thomas ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

N Hydroxy N aminoguanidines; N Hydroxysemicarbazides; Pharmacophore modeling; QSAR; Ribonucleotide Reductase

Indexed keywords

AMINOGUANIDINE; N HYDROXY N' AMINOGUANIDINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PHARMACOPHORE; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GUANIDINES; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SMALL MOLECULE LIBRARIES;

EID: 79956076107     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.009     Document Type: Article

References (21)

1. P.B. Koneru, E.J. Lien, and V.I. Avramis Pharm. Res. 10 1993 515
2. A.W. Tai, E.J. Lien, M.M. Lai, and T.A. Khwaja J. Med. Chem. 27 1984 236
3. A. T'Ang, E.J. Lien, and M.M. Lai J. Med. Chem. 28 1985 1103
4. B. van't Riet, G.L. Wampler, and H.L. Elford J. Med. Chem. 22 1979 589
5. S. Ren, R. Wang, K. Komatsu, P. Bonaz-Krause, Y. Zyrianov, C.E. McKenna, C. Csipke, Z.A. Tokes, and E.J. Lien J. Med. Chem. 45 2002 410
6. K.C. Fylaktakidou, D.J. Hadjipavlou-Litina, K.E. Litinas, E.A. Varella, and D.N. Nicolaides Curr. Pharm. Des. 14 2008 1001
7. G. Nocentini Crit. Rev. Oncol. Hematol. 22 1996 89
8. A.M. Tsimberidou, Y. Alvarado, and F.J. Giles Expert. Rev. Anticancer Ther. 2 2002 437
9. N.M. Cerqueira, S. Pereira, P.A. Fernandes, and M.J. Ramos Curr. Med. Chem. 12 2005 1283
10. J. Shao, B. Zhou, L. Zhu, A.J. Bilio, L. Su, Y.C. Yuan, S. Ren, E.J. Lien, J. Shih, and Y. Yen Biochem. Pharmacol. 69 2005 627
11. J. Shao, B. Zhou, B. Chu, and Y. Yen Curr. Cancer Drug Targets 6 2006 409
12. A. Basu, K. Jasu, V. Jayaprakash, N. Mishra, P. Ojha, and S. Bhattacharya Eur. J. Med. Chem. 44 2009 2400
13. P. Dewangan, S. Verma, and A. Basu Lett. Drug Des. Discovery 5 2008 494
14. PHASE procedure. Six built-in types of pharmacophoric features: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H), negative ionizable (N), positive ionizable (P), and aromatic ring (R). Ligands were processed with the LigPrep program to assign protonation states appropriate for pH 7.0. Conformer generation was carried out with the MacroModel. Potentials were computed using the OPLS2005 force field. The default pharmacophore feature definitions were used in site generation. After the identification of the sites hypotheses were generated by a systematic variation of the number of sites. The number of matching active compounds was kept default of 39 (entire training set). All the molecules were considered as active no active/inactive threshold were assigned. The scoring was done using: Survival score formula = (Vector score) + (Site score) + (Volume score) + (Selectivity score) + (Number of matches-1)-(Reference ligand relative conformational energy) + (Ref ligand activity). Max intersite distance=2.00, initial and final box size is 20 and 1, respectively. The best hypothesis was chosen based on the survival score by PHASE. The top scored hypothesis was then used to build pharmacophore-based 3D QSAR models with 3 PLS factors and Grid spacing = 1.
15. P. Roy, and K.Q.S.A.R. Roy Comb. Sci. 27 2008 302
16. I. Mitra, A. Saha, and K. Roy Molecular Simulation 36 2010 1067
17. A. Schüller, G. Schneider, and E.Q.S.A.R. Byvatov Comb. Sci. 22 2003 719
18. 9), δ 8.67(s, 1H, CH), δ 9.25(s, 1H, NH), δ 10.52s, 1H, NH), δ 11.32 (s, 1H, OH).
19. P. Saiko, M. Ozsvar-Kozma, A. Bernhaus, M. Jaschke, G. Graser, A. Lackner, M. Grusch, Z. Horvath, S. Madlener, G. Krupitza, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, and T. Szekeres Int. J. Oncol. 31 2007 1261
20. S. Madlener, C. Illmer, Z. Horvath, P. Saiko, A. Losert, I. Herbacek, M. Grusch, H.L. Elford, G. Krupitza, A. Bernhaus, M. Fritzer-Szekeres, and T. Szekeres Cancer Lett. 245 2007 156
21. P. Saiko, G. Graser, B. Giessrigl, A. Lackner, M. Grusch, G. Krupitza, A. Basu, B. Sinha, V. Jayaprakash, and W. Jaeger Biochem. Pharmacol. 81 2011 50